Laboratory of Signalling and Cell Fate, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK.
Biochem Soc Trans. 2012 Feb;40(1):251-6. doi: 10.1042/BST20110663.
The MEK5 [MAPK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated kinase) kinase 5]/ERK5 pathway is the least well studied MAPK signalling module. It has been proposed to play a role in the pathology of cancer. In the present paper, we review the role of the MEK5/ERK5 pathway using the 'hallmarks of cancer' as a framework and consider how this pathway is deregulated. As well as playing a key role in endothelial cell survival and tubular morphogenesis during tumour neovascularization, ERK5 is also emerging as a regulator of tumour cell invasion and migration. Several oncogenes can stimulate ERK5 activity, and protein levels are increased by a novel amplification at chromosome locus 17p11 and by down-regulation of the microRNAs miR-143 and miR-145. Together, these finding underscore the case for further investigation into understanding the role of ERK5 in cancer.
MEK5 [丝裂原活化蛋白激酶/细胞外信号调节激酶激酶 5]/ERK5 通路是研究最少的 MAPK 信号转导模块。它被认为在癌症的发病机制中发挥作用。在本文中,我们使用“癌症特征”作为框架来回顾 MEK5/ERK5 通路的作用,并考虑该通路如何失调。ERK5 在肿瘤新生血管形成过程中内皮细胞存活和管状形态发生中起关键作用,同时也作为肿瘤细胞侵袭和迁移的调节剂而出现。几种癌基因可以刺激 ERK5 的活性,并且通过在染色体 17p11 位置的新扩增和 microRNA miR-143 和 miR-145 的下调来增加蛋白水平。这些发现共同强调了进一步研究 ERK5 在癌症中的作用的必要性。